Fig. 2: Change from baseline in disease severity scores over the study period. | Nature Medicine

Fig. 2: Change from baseline in disease severity scores over the study period.

From: BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial

Fig. 2: Change from baseline in disease severity scores over the study period.The alternative text for this image may have been generated using AI.

Mean (95% CI) change from baseline over 3 months for placebo and over 12 months for Descartes-08 in MG-ADL (a), QMG (b), MGC (c) and MG-QoL-15r (d) scores. Direction of improvement is indicated by decreasing scores. Horizontal dotted line represents the threshold for a clinically meaningful decrease. D, day; M, month.

Back to article page